Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001437749-22-011925
Filing Date
2022-05-11
Accepted
2022-05-11 16:35:33
Documents
54
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q mbrx20220331_10q.htm   iXBRL 10-Q 640383
2 EXHIBIT 31.1 ex_347762.htm EX-31.1 13417
3 EXHIBIT 31.2 ex_347763.htm EX-31.2 13250
4 EXHIBIT 32.1 ex_347764.htm EX-32.1 6692
5 EXHIBIT 32.2 ex_347765.htm EX-32.2 6773
11 moleculinnewlogoresized.jpg GRAPHIC 7783
  Complete submission text file 0001437749-22-011925.txt   3439367

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA mbrx-20220331.xsd EX-101.SCH 40622
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE mbrx-20220331_cal.xml EX-101.CAL 29128
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE mbrx-20220331_def.xml EX-101.DEF 236491
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE mbrx-20220331_lab.xml EX-101.LAB 218969
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mbrx-20220331_pre.xml EX-101.PRE 256184
48 EXTRACTED XBRL INSTANCE DOCUMENT mbrx20220331_10q_htm.xml XML 436690
Mailing Address 5300 MEMORIAL DRIVE SUITE 950 HOUSTON TX 77007
Business Address 5300 MEMORIAL DRIVE SUITE 950 HOUSTON TX 77007 713-300-5160
Moleculin Biotech, Inc. (Filer) CIK: 0001659617 (see all company filings)

EIN.: 474671999 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37758 | Film No.: 22914336
SIC: 2834 Pharmaceutical Preparations